The precise characterization and activity validation of CD3 antigen serve as the quality cornerstone in the development of bispecific antibody drugs.

In the global development history of therapeutic antibodies, OKT3, as the first approved monoclonal antibody, holds milestone significance, pioneering the use of antibodies for targeted treatment of human diseases. With the evolution of antibody engineering technologies, bispecific and multispecific antibodies have become cutting-edge directions in tumor immunotherapy, and the CD3 antigen has once again become a focus for drug developers. Statistics show that among bispecific antibodies in clinical research stages, nearly half target the CD3 antigen as one of their key targets, fully demonstrating CD3's central bridging role in mediating T-cell anti-tumor immunity.

However, the development of CD3-targeting antibodies does not pursue infinitely high affinity but requires a delicate balance between efficacy and safety. Extensive literature indicates that for bispecific antibodies to achieve optimal anti-tumor activity, the affinity of their CD3-binding arm to the CD3 antigen must fall within a narrow "therapeutic window." Specifically, if the affinity is too strong (below 10 nM), it may lead to excessive T-cell activation in non-tumor tissues, triggering cytokine release syndrome (CRS) and posing serious safety risks. Conversely, if the affinity is too weak (above 100 nM), it may fail to effectively recruit and activate T cells in the tumor microenvironment, resulting in poor anti-tumor effects. Therefore, precisely controlling the CD3-binding affinity within the 10 nM to 100 nM range is a key design parameter for achieving optimal in vivo efficacy of bispecific molecules.

This shift in the development paradigm marks a transition in antibody drug screening strategies from merely pursuing "high affinity" to seeking "appropriate affinity." Whether it's the CD3 arm in bispecific antibodies, immune agonist targets (e.g., CD137) antibodies, or CD19 antibodies on CAR-T cell surfaces aimed at improving safety, the accurate quantification of affinity has become a core attribute parameter determining drug safety and efficacy. The reliability of affinity measurements fundamentally depends on a fully activity-validated, conformationally homogeneous, and stable antigen reagent. "Without the skin, where would the hair attach?" If the antigen itself is flawed, the affinity data derived from it become meaningless. Based on this, this article systematically reviews the structural characteristics, quality control standards, and activity validation strategies of CD3 antigens, and discusses the necessity and importance of high-quality antigens in early antibody drug discovery and preclinical evaluation.

The CD3 molecule is a transmembrane protein complex expressed on the surface of T cells, belonging to the immunoglobulin superfamily. In humans, the CD3 complex consists of four subtypes: CD3δ (CD3D), CD3ε (CD3E), CD3γ (CD3G), and CD3ζ (CD3Z). Among these, CD3δ and CD3ε exist as heterodimers, and CD3γ and CD3ε also form heterodimers. These heterodimers further non-covalently bind with the α and β chains of the T-cell receptor (TCR) to form the complete TCR-CD3 signal transduction complex. When the major histocompatibility complex (MHC)-peptide complex on antigen-presenting cells (APCs) binds to the TCR, the CD3 complex transmits the extracellular recognition signal across the membrane to the intracellular space, initiating the T-cell activation cascade.

In the context of antibody drug development, "targeting CD3" typically refers narrowly to targeting the human CD3ε subunit (UniProt ID: P07766). However, CD3ε does not exist as an isolated monomer on the T-cell surface but must form heterodimers with CD3δ or CD3γ to maintain its native conformation and biological function. This characteristic poses significant challenges for antigen reagent design: when CD3ε exists in a monovalent state, its protein flexibility may lead to spatial conformations significantly different from those in the heterodimer state. During co-expression, due to the similar molecular weights of CD3δ and CD3ε, non-intended homodimers or mismatched aggregates can easily form. Therefore, the ability to prepare structurally homogeneous, conformationally correct heterodimer antigens that closely resemble the CD3ε epitope in the natural TCR-CD3 complex directly determines the biological relevance of subsequent antibody screening and affinity measurements.

Meeting purity standards is only a necessary but insufficient condition for antigen quality; more critical is the validation of its biological activity. Activity validation aims to answer a core question: Can the antigen correctly display its epitope in a manner similar to the natural CD3 complex and maintain expected binding activity and kinetic characteristics with its specific binding molecules (e.g., OKT3 antibody, clinical-stage bispecific molecules)?

Standardized activity validation typically includes the following levels: (1) Affinity measurement using surface plasmon resonance (SPR) or bio-layer interferometry (BLI), calibrating antigen batches with control antibodies of known affinity ranges (e.g., OKT3 and its variants) to ensure their affinity values fall within the acceptable range reported in the literature; (2) Cell-based binding validation, using CD3-positive T-cell lines or primary T cells for flow cytometry analysis to confirm the antigen can recognize and occupy the corresponding epitope on the natural cell surface CD3 complex; (3) Functional validation based on reporter gene systems, such as using NFAT-responsive element-driven luciferase reporter gene T-cell lines to assess the antigen's ability to mediate TCR signaling pathway activation, thereby comprehensively judging the antigen's conformational integrity and biological relevance.

Only antigens that pass such multi-level activity validation can serve as reliable detection reagents for affinity ranking of bispecific molecules, kinetic dissociation constant (KD) measurement, and as controls in cell function experiments. Antigens lacking thorough activity validation often exhibit epitope shielding, conformational inactivation, or excessive heterogeneity, leading to measured affinity data deviating from true values and thereby misleading affinity optimization decisions for antibody molecules.

As antibody drug development logic shifts from "strong binding" to "appropriate binding," precise affinity quantification has risen from an auxiliary parameter to a key attribute determining the success or failure of candidate molecules. For CD3 bispecific antibodies, subtle deviations in affinity (e.g., from 20 nM to 80 nM) may significantly alter their tissue distribution, tumor localization efficiency, and cytokine release profiles, thereby affecting the clinical therapeutic index. Similarly, for immune agonist antibodies, overly strong affinity may lead to excessive receptor cross-linking and systemic immune storms, while overly weak affinity may fail to effectively activate anti-tumor immune responses. In the CAR-T cell therapy field, CD19 CAR affinity design also follows the "moderate is optimal" principle, as high-affinity CARs may accelerate T-cell exhaustion or cause off-target toxicity.

In this context, using rigorously activity-validated CD3 antigens for SPR or microscale thermophoresis (MST) affinity measurements has become an indispensable standard process in the early discovery phase of antibody drugs. Simultaneously, as regulatory agencies increasingly demand higher standards for biologics quality control, batch release testing and stability monitoring of antigen reagents also rely on robust activity validation methodologies for support.

In the commercial supply of CD3 antigen reagents, Nanjing UAbio Biotechnology Co., Ltd. offers recombinant CD3 heterodimer protein products that undergo stringent design and quality control. UAbio's product line includes Biotinylated CD3E & CD3D Fc, His, Avi tag & Fc, Flag, Avi tag Heterodimer Protein, Human (CD3 epsilon & CD3 delta, also known as CD3E & CD3D or CD3 delta & CD3 epsilon). This product ensures correct heterodimer assembly through co-expression strategies and multi-step purification processes, and features biotinylation (Avi tag) for easy conjugation with streptavidin-coated sensor chips or magnetic beads, making it suitable for various affinity analysis and binding detection platforms such as SPR, BLI, ELISA, and flow cytometry. The protein product undergoes rigorous high-performance liquid chromatography (HPLC) purity testing, peptide mapping, and control antibody-based activity validation, with batch-to-batch consistency and stability meeting the strict standards for early antibody screening and affinity quantification, providing customers with reliable CD3 antigen detection tools.